Medimaps Group develops patented image-processing and deep‑learning applications to assess bone quality and micro‑architecture from routinely acquired medical images. Its flagship product, TBS iNsight, provides bone texture analysis to help clinicians identify patients earlier and classify fracture risk without additional radiation exposure. TBS iNsight has been used in clinical practice worldwide, is included in many guidelines, supported by over 800 peer‑reviewed publications, and is used by more than 30,000 physicians. The company reports that TBS has reclassified roughly 30% of osteopenic patients in studies. Medimaps’ technology is a patented multi‑layer deep learning approach applicable across image modalities, supporting opportunistic X‑ray screening, patient risk profiling, and presurgical assessment. Medimaps announced it secured $20 million in an institutional investment round to expand and commercialize its AI product portfolio. The funds will be used to develop and market‑launch its patented AI applications for bone health assessment in the U.S., Europe, Asia, and Latin America.

Total raised

$20M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2021